J. Santos

发表

Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus

A. Hemminki, M. Siurala, S. Tähtinen, 2018, Molecular therapy oncolytics.

Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control

A. Hemminki, A. Kanerva, Sadia Zafar, 2021, Frontiers in Immunology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling

A. Hemminki, A. Kanerva, R. Havunen, 2020, Cells.

Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes

A. Hemminki, A. Kanerva, Sadia Zafar, 2020, Cancer Gene Therapy.

CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy

T. D. de Gruijl, Hongjie Wang, A. Hemminki, 2018, Oncoimmunology.

Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy

D. Nettelbeck, A. Hemminki, M. Siurala, 2016, Molecular therapy oncolytics.

Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers

A. Hemminki, A. Kanerva, Sadia Zafar, 2021, Cells.

Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity

T. D. de Gruijl, A. Hemminki, M. Siurala, 2020, Journal for ImmunoTherapy of Cancer.

Modulation of the tumor microenvironment with an oncolytic adenovirus for effective T-cell therapy and checkpoint inhibition.

A. Hemminki, R. Havunen, J. Santos, 2020, Methods in enzymology.

Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression

A. Hemminki, A. Kanerva, O. Hemminki, 2022, Oncoimmunology.

Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers

A. Hemminki, A. Kanerva, J. Tapper, 2022, Diseases.

Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1

A. Hemminki, A. Kanerva, R. Havunen, 2022, Oncoimmunology.

Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition

A. Hemminki, M. Siurala, A. Kanerva, 2020, Oncoimmunology.

Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer

T. Salo, A. Hemminki, K. Aro, 2022, Frontiers in Immunology.

Constitutively active GSK3β as a means to bolster dendritic cell functionality in the face of tumour-mediated immune suppression

T. D. de Gruijl, H. Verheul, J. Joore, 2019, Oncoimmunology.

Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy.

A. Hemminki, M. Siurala, A. Kanerva, 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Adenoviral production of interleukin‐2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy

A. Hemminki, M. Siurala, S. Tähtinen, 2017, International journal of cancer.

Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors

A. Hemminki, M. Siurala, A. Kanerva, 2020, Molecular therapy oncolytics.

Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1

T. D. de Gruijl, A. Hemminki, A. Kanerva, 2021, Frontiers in Immunology.

Oncolytic adenovirus ORCA-010 activates pro-inflammatory myeloid cells and facilitates T cell recruitment and activation by PD-1 blockade in melanoma.

T. D. de Gruijl, A. Hemminki, V. V. van Beusechem, 2021, Human gene therapy.

Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors

A. Hemminki, A. Kanerva, R. Havunen, 2022, Molecular Therapy: Oncolytics.

Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1

A. Hemminki, M. Siurala, R. Havunen, 2021, Cells.

Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting

I. Vattulainen, A. Hemminki, V. Cerullo, 2023, Frontiers in Immunology.

Abstract B16: Enabling checkpoint inhibitors with oncolytic viruses to deliver complete responses: A matter of timing

A. Hemminki, M. Siurala, R. Havunen, 2020 .

An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage

A. Hemminki, R. Havunen, J. Santos, 2023, Frontiers in immunology.

Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer

A. Hemminki, A. Kanerva, O. Hemminki, 2023, Oncoimmunology.

Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy.

A. Hemminki, M. Siurala, A. Kanerva, 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.